GleamWall
中文EN

PAHC PHIBRO ANIMAL HEALTH CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 1069899 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.1%
TTM net income YoY51.5%
TTM EPS YoY49.7%
Revenue 3-yr CAGR16.4%
Net income 3-yr CAGR70.5%

Margins

Gross margin33.8%
Operating margin12.5%
Net margin6.7%
FCF margin1.4%
EBITDA margin15.9%

Returns

ROE28.2%
ROA7.1%
ROIC (approx.)15.6%
Asset turnover1.06x

Leverage & solvency

Liabilities / assets72.4%
Debt / equity1.46x
Current ratio3.20x
Interest coverage4.18x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio1.2%
Payout ratio19.0%
Capex / revenue4.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$1.52B$1.30B
Cost of revenue$1.01B$896.27M
Gross profit$512.51M$399.94M
R&D expense$24.55M$23.73M
SG&A expense$318.12M$289.48M
Operating income$194.40M$110.47M
Interest expense$46.42M$37.22M
Pretax income$137.35M$67.99M
Income tax$37.63M$19.73M
Net income$99.72M$48.26M
EBITDA$245.91M$156.07M
EPS (basic)2.461.19
EPS (diluted)2.431.19
Dividends declared per share0.480.48
Weighted avg. shares (diluted)40.96M40.68M
Balance sheet
Cash & equivalents$61.42M$68.04M
Short-term investments$20.57M$9.00M
Receivables$238.79M$227.98M
Inventory$534.88M$444.43M
Current assets$935.51M$810.61M
PP&E, net$369.17M$354.69M
Goodwill$60.05M$59.65M
Intangibles$30.05M$36.47M
Total assets$1.50B$1.36B
Current liabilities$316.47M$293.47M
Short-term debt$25.02M$16.25M
Long-term debt$591.77M$615.43M
Total debt$616.79M$631.68M
Total liabilities$1.12B$1.08B
Shareholders' equity$385.48M$285.68M
Net debt$555.38M$563.65M
Cash flow statement
Operating cash flow$68.95M$80.12M
Capital expenditure$59.09M$38.29M
Free cash flow$9.87M$41.83M
Investing cash flow-$71.45M-$288.69M
Financing cash flow-$6.56M$207.13M
Depreciation & amortization$51.51M$45.60M
Stock-based compensation$1.60M$717,000
Dividends paid$19.46M$19.45M

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.